Axogen, Inc. (AXGN) stock
AXGNNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 11/30142% above fair value
$55.37−0.01 (-0.02%)
Close on Nov 17, 2026Market cap $3.31BP/E –Yield –
Axogen r&d expenses
Research and development expenses are spending on new products and technology.
Axogen's R&D Expenses for the twelve months ending Sep 30, 2026 was $37.43M, up 37.6% year over year. For fiscal 2025 it was $32.89M, up 18.4% from the year before. Over ten years it grew 26.1% a year on average. The highest annual figure on record is $32.89M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $32.89M | +18.4% |
| FY2024 | Dec 31, 2024 | $27.77M | +1.6% |
| FY2023 | Dec 31, 2023 | $27.34M | +6.7% |
| FY2022 | Dec 31, 2022 | $25.63M | +6.0% |
| FY2021 | Dec 31, 2021 | $24.18M | +35.5% |
| FY2020 | Dec 31, 2020 | $17.85M | +1.9% |
| FY2019 | Dec 31, 2019 | $17.51M | +48.8% |
| FY2018 | Dec 31, 2018 | $11.77M | +75.7% |
| FY2017 | Dec 31, 2017 | $6.70M | +59.0% |
| FY2016 | Dec 31, 2016 | $4.21M | +30.1% |
| FY2015 | Dec 31, 2015 | $3.24M | +6.7% |
| FY2014 | Dec 31, 2014 | $3.03M | +42.7% |
| FY2013 | Dec 31, 2013 | $2.13M | +48.9% |
| FY2012 | Dec 31, 2012 | $1.43M | +104.7% |
| FY2011 | Dec 31, 2011 | $697.36K | +59.9% |
| FY2010 | Dec 31, 2010 | $436.01K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $8.95M | +18.3% |
| Q2 FY2026 | Jun 30, 2026 | $8.59M | +25.3% |
| Q1 FY2026 | Mar 31, 2026 | $7.52M | +23.4% |
| Q4 FY2025 | Dec 31, 2025 | $12.38M | +84.6% |
| Q3 FY2025 | Sep 30, 2025 | $7.57M | +8.1% |
| Q2 FY2025 | Jun 30, 2025 | $6.85M | +2.9% |
| Q1 FY2025 | Mar 31, 2025 | $6.09M | -17.8% |
| Q4 FY2024 | Dec 31, 2024 | $6.70M | -6.6% |
| Q3 FY2024 | Sep 30, 2024 | $7.00M | +4.5% |
| Q2 FY2024 | Jun 30, 2024 | $6.66M | -6.8% |
| Q1 FY2024 | Mar 31, 2024 | $7.41M | +17.1% |
| Q4 FY2023 | Dec 31, 2023 | $7.18M | +35.9% |
| Q3 FY2023 | Sep 30, 2023 | $6.69M | -5.0% |
| Q2 FY2023 | Jun 30, 2023 | $7.14M | +1.7% |
| Q1 FY2023 | Mar 31, 2023 | $6.33M | +0.8% |
| Q4 FY2022 | Dec 31, 2022 | $5.28M | -16.2% |
| Q3 FY2022 | Sep 30, 2022 | $7.05M | +10.1% |
| Q2 FY2022 | Jun 30, 2022 | $7.02M | +22.7% |
| Q1 FY2022 | Mar 31, 2022 | $6.28M | +9.2% |
| Q4 FY2021 | Dec 31, 2021 | $6.30M | +27.8% |
| Q3 FY2021 | Sep 30, 2021 | $6.40M | +51.4% |
| Q2 FY2021 | Jun 30, 2021 | $5.72M | +40.6% |
| Q1 FY2021 | Mar 31, 2021 | $5.75M | +24.6% |
| Q4 FY2020 | Dec 31, 2020 | $4.93M | +0.4% |
| Q3 FY2020 | Sep 30, 2020 | $4.23M | +1.2% |
| Q2 FY2020 | Jun 30, 2020 | $4.07M | -4.9% |
| Q1 FY2020 | Mar 31, 2020 | $4.61M | +11.5% |
| Q4 FY2019 | Dec 31, 2019 | $4.91M | +29.1% |
| Q3 FY2019 | Sep 30, 2019 | $4.18M | +26.4% |
| Q2 FY2019 | Jun 30, 2019 | $4.28M | +64.6% |
| Q1 FY2019 | Mar 31, 2019 | $4.14M | +101.1% |
| Q4 FY2018 | Dec 31, 2018 | $3.81M | +93.1% |
| Q3 FY2018 | Sep 30, 2018 | $3.31M | +84.2% |
| Q2 FY2018 | Jun 30, 2018 | $2.60M | +71.0% |
| Q1 FY2018 | Mar 31, 2018 | $2.06M | +45.8% |
| Q4 FY2017 | Dec 31, 2017 | $1.97M | +67.3% |
| Q3 FY2017 | Sep 30, 2017 | $1.80M | – |
| Q2 FY2017 | Jun 30, 2017 | $1.52M | – |
| Q1 FY2017 | Mar 31, 2017 | $1.41M | – |
| Q4 FY2016 | Dec 31, 2016 | $1.18M | – |
See a number that looks wrong?